Close Menu

antibodies

MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.

The company's commercial testing continues to focus on patients with identified lung nodules, but the new data is the strongest yet to support a shift to upfront cancer detection.

The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.

The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.

The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.

The firms will use AbCellera's antibody discovery platform, which combines a variety of technologies including next-generation sequencing and bioinformatics.

As part of the Human Vaccines Project, researchers sequenced samples from three adults and three infants to identify sets of shared and unique circulating B cell receptors.

The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.

The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.

The custom-made software will also allow Twist's biopharmaceutical customers to access a proprietary G-protein coupled receptor target library.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.